BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
|Articles|January 1, 2020
- Pharmaceutical Executive-01-01-2020
- Volume 40
- Issue 1
Pharmaceutical Executive, January 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive January 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 7 years ago
Pharm Exec’s 2020 Industry Outlookalmost 7 years ago
Sharing the Pricing Stage in 2020almost 7 years ago
Paving Bayer’s Future Pathalmost 7 years ago
Politics & Pricing to Shape Pharma Prospects in 2020almost 7 years ago
Pharma’s Brexit Routealmost 7 years ago
Is the Tail Wagging the Dog in Drug Market Entry?almost 7 years ago
A Happy New Year for European Pharma Policy?almost 7 years ago
Deeper Dive: Gene Therapy Manufacturingalmost 7 years ago
Country Report: ChinaAdvertisement
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Rebuilding Clinical Data Workflows for the AI Era
3
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5